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Abstract
Short tandem repeats (STRs) are scattered throughout the human genome. Some STRs, like trinucleotide repeat expansion
(TRE) variants, cause hereditable disorders. Unambiguous molecular diagnostics of TRE disorders is hampered by current
technical limitations imposed by traditional PCR and DNA sequencing methods. Here we report a novel pipeline for TRE
variant diagnosis employing the massively parallel sequencing (MPS) combined with an opensource software package
(FDSTools), which together are designed to distinguish true STR sequences from STR sequencing artifacts. We show that
this approach can improve TRE diagnosis, such as Oculopharyngeal muscular dystrophy (OPMD). OPMD is caused by a
trinucleotide expansion in the PABPN1 gene. A short GCN expansion, (GCN[10]), coding for a 10 alanine repeat is not
pathogenic, but an alanine expansion is pathogenic. Applying this novel procedure in a Dutch OPMD patient cohort, we
found expansion variants from GCN[11] to GCN[16], with the GCN[16] as the most abundant variant. The repeat expansion
length did not correlate with clinical features. However, symptom severity was found to correlate with age and with the
initial affected muscles, suggesting that aging and muscle-speciﬁc factors can play a role in modulating OPMD.
Introduction
STR sequences are widely spread over the genome and
rarely directly related to inherited diseases [1]. However,
some STRs, especially those where a single repeat unit
encodes for an amino acid, are disease associated. A well-
known example is a small group of TRE disorders, most of
which are associated with hereditable disorders that often
lead to neurological or neuromuscular symptoms [2–4].
These disorders can vary in symptom heterogeneity, the age
of onset and can show a varied progression pattern, which
together complicate clinical diagnosis [2, 3]. Therefore, a
deﬁnite diagnosis of TRE variants should be determined by
a DNA-based genotyping. Accurate molecular diagnosis of
short TRE disorders is technically challenging, as traditional
DNA sequencing methods and PCR-based ampliﬁcation
methods impose limitations for TRE diagnosis [5–7].
STR ampliﬁcation is prone to stutter artifacts, thereby
creating noise in DNA sequencing data [8]. High coverage
sequencing data in STR regions can be generated using
massively parallel sequencing (MPS) and combinning with
statistical algorithms, the stutter characteristics and ratios
can be accuratly determined [9]. This approach has been
proven successful in STRs-based genotyping for forensic
studies [10, 11]. Here we assessed whether MPS can be
applied for accurate molecular diagnosis for TREs in
Oculopharyngeal muscular dystrophy (OPMD).
OPMD (OMIM #164300) is caused by a short TRE in
the ﬁrst exon of the gene encoding for the polyadenylate-
binding protein nuclear 1 (NG_008239.1 RefSeq gene on
chromosome 14q11) [12]. The TRE in PABPN1 is an
example of STRs located in coding regions. In the wild-type
PABPN1 allele, the ﬁrst methionine (ATG) is followed by a
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10 alanine repeat (NM_004643: GCG[7]GCA[3]; named
here as GCN[10], N represents A or G). A pathogenic
PABPN1 was reported to have an 11 to 18 alanine range
(GCN[11] to GCN[18], also referred as +1 to +8) [12]. The
pathogenic protein is misfolded and aggregated, and con-
sequently hampers cellular activities [3]. Most OPMD
patients are heterozygous, with GCN[13] as the most
abundant pathogenic expansion. Only a few homozygous
cases were reported (GCN[13], GCN[11]) [12–15].
OPMD is a rare disorder (the prevalence is estimated at
1:100,000), but several studies suggested that OPMD is
under and/or misdiagnosed [6, 7, 16, 17], due to unfami-
liarity of clinicians, and due to the type of DNA test. Most
often, Sanger sequencing is used for DNA diagnosis in
OPMD. However, Sanger sequencing is not reliable for
TRE sequencing because of low sequencing depth. More-
over, it can not accurately distinguish between two alleles
that differ in length. The MPS will be suitable since this
method sequences both alleles many times instead of
resulting in one combined signal shown in an electro-
pherogram. Current bioinformatics tools can provide an
accurate analysis of STRs with massively parallel amplicon
sequencing data [9]. Reliable and accurate genotyping of
diseases caused by STRs is essential for an assessment of
phenotype–genotype relations.
Materials and methods
Bioﬂuid collection and DNA isolation
Patients were recruited through the Dutch neuromuscular
database (Computer Registry of All Myopathies and Poly-
neuropathies: CRAMP). All participants signed informed
consent and the study was approved by the local ethics
committee. All patients visited the outpatient clinic at the
Radboud University Medical Centre and were clinically
examined on swallowing function, presence of ptosis and
muscle weakness. Summary of clinical details are found in
Table S1. Saliva was collected from patients and healthy
controls for DNA analysis. Blood was collected from
anonymous controls.
Sample preparation
DNA was extracted from saliva that was collected from the
OPMD subjects. The saliva was collected at room tem-
perature, and RNAprotect® Saliva reagent (Qiagen) was
added to the tube, according to the manufacturer’s instruc-
tion to stabilize RNA. Samples were kept in −80 °C prior to
DNA isolation. DNA isolation was carried out with Trizol
(Invitrogen) according to the manufacturer’s instructions.
DNA quality was determined with the Qubit 4 ﬂuorometer
(ThermoFisher Scientiﬁc). Control samples were collected
from anonymous subjects, from whom DNA was isolated
from blood, as described in [18]. PCR was conducted with
1–5 ng DNA and 10 pmole PABPN1-speciﬁc primers tar-
geting a 251 bp region including the GCN stretch in the ﬁrst
exon. Primers to PABPN1 were designed with the Primer3
online tool (Table S2). These PABPN1-speciﬁc primers
contained two different tails at the 5′ end of the primers,
allowing a second PCR to incorporate the Illumina adapter
sequences with barcoded primers (Table S2A) targeting the
tails from the ﬁrst PCR. In summary, PCR and library
preparation is performed with two PCR reactions. First an
ampliﬁcation of PABPN1 using PABPN1_F and
PABPN1_R primer set (Table S2), and a second PCR was
performed with a multiplex barcoded primer set
(Table S2B). Ampliﬁcation performance of PABPN1 was
evaluated with three PCR kits: KAPA HiFi PCR (Roche),
NEB Q5 kit (New England Biology) and AccuPri-
me™(ThermoFisher), according to the manufacturer’s
instructions. Consistent results were obtained only with the
KAPA HiFi PCR kit. PCR ampliﬁcation was carried out
with the following PCR program: 5 min denaturation at 98 °
C, 30 times (10 s at 98 °C, 30 s at 60 °C, 30 s at 72 °C), and
ﬁnal extension for 3 min at 72 °C. PCR products were
measured with 2100 Bioanalyzer High Sensitivity DNA
Assay (Agilent Genomics). Subsequently, a clean-up was
performed on the PCR products with Agencourt AMPure
XP-beads (Beckman Coulter) according to the manu-
facturer’s instructions using a bead/sample ratio of 1.2×.
Sample-speciﬁc barcoding was carried out in the second
PCR with dual barcoded primers (Table S2B), using the
same PCR program but for only 12 PCR cycles. Another
PCR clean-up was performed with Agencourt AMPure XP-
beads and the puriﬁed libraries were analyzed with the 2100
Bioanalyzer High Sensitivity DNA Assay (Agilent Geno-
mics). In Fig. 2 at the left panel, we show the traces that
were generated by the 2100 Bioanalyzer application prior to
MiSeq sequencing.
Sequencing and analysis
Two times 300 bp paired-end MPS data were generated
using the MiSeq®Sequencer (Illumina) with the Miseq
reagents v3 600 cycles kit. A summary of the procedure is
shown in Fig. 1. DNAseq analysis, sample ﬁltering and data
interpretation were carried out with FDSTools as detailed in
[9]. In brief: Read-pairs were merged after alignment.
Merged reads were mapped to PABPN1 using annotation.
TSV, which counts and summarizes all sequenced reads that
include the PABPN1 primer sequences (with a mismatch
allowance of 10%). All reads within a sample with a fre-
quency of one were ﬁltered out and clustered into a single
“other sequences”. A distinction between noise and true
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allelic sequences was made from the FDSTools visualiza-
tions. The allele with most reads and proper sequence
structure was considered as a genuine allele in the sample.
Heterozygosity was determined by the second most fre-
quent allele that had a sequencing depth above the
minimum threshold (we set it for N= 10). We found that
the depth of the pathogenic allele was on average 56.5%
of the wild-type allele in a Dutch OPMD cohort. PCR
and sequencing artifacts like STR-stutter and point muta-
tions can be recognized by FDSTools when a database
with known genotypes is supplied. In this study manual
analysis of the FDStools visualizations was used for
genotyping, since a known OPMD database is currently
lacking. The data was then uploaded into LOVD.nl,
creating the ﬁrst OPMD variant database. Sequences
and corresponding read depth were used to distinguish
PCR and sequencing artefacts from genuine alleles. The
“Other sequences” that are shown in Fig. 2 include all
reads that did not meet the criteria to be shown in the
FDSTools ﬁgures. These criteria are user depended
and were set to a minimum of 10 reads and a minimum
of 0.5% from the highest PAPBN1 allele in the sample.
DNA diagnostic results are found in Table S1. Statistical
tests were made in Prism 7.
Results and discussion
DNA from 50 putative OPMD patients (Table S1) and 25
anonymous healthy controls was ﬁrst ampliﬁed using
PABPN1-speciﬁc primers, and subsequently ampliﬁed with
sample-speciﬁc barcoded Illumina compatible primers
(Table S2). Results of multiplex sequencing in sufﬁcient
depth was then analysed using FDSTools, which identiﬁes
PCR stutters, and subsequently determines genuine alleles
that were then manually considered for genotyping (Fig. 1).
FDSTools is an open-source software package that can
interactively visualize amplicon sequencing data. When
FDStools is supplied with deep sequencing data from a
known OPMD database, it can create a noise database and
use this to determine and visualize systemic noise like
stutter alleles and sequencing artefacts in the amplicon
sequencing data. Moreover, FDStools is able to automate
allele calling [9]. In this study, allele calling was manually
made from the FDStools visualization output, since such
an MPS database for PABPN1 variants is not yet available.
The FDSTools output shows the statistics and number of
reads for each sequence per subject (examples are in Fig. 2).
The proportion of reads per sequence is calculated from the
most frequent sequence found in the sample (denoted the
most frequent sequence as 100%). All other sequences
are denoted with a percentage relative to this depth
(examples are in Fig. 3). Allele calling is made by the
two most frequent sequences.
Prior to sequencing, PCR products were analyzed with
the Agilent 2100 Bioanalyzer (Fig. 2, left panel). Two
peaks, corresponding to the wild-type and expanded
alleles in DNA from heterozygous patients with long
expansion variants GCN[13–16], were found in the DNA
Bioanalyzer output (Fig. 2, left panel). MPS sequencing and
FDSTools analysis also showed two alleles in patients
carrying the GCN[13–16] variants (Fig. 2, right panel). This
indicates heterozygosity in those patients. In control sub-
jects only a single peak was found with the DNA Bioana-
lyzer (Fig. 2, left panel), and accordingly only one genuine
allele (GCN[10]) was identiﬁed using MPS sequencing and
FDSTools analysis (Fig. 2, right panel). The short expan-
sion variants (GCN(11–12) were detected only with MPS
and FDSTools analysis (Fig. 2, right panel). The resolution
of the DNA Bioanalyzer was insufﬁcient to separate
between GCN[10] and GCN[12] (Fig. 2, left panel).
Additionaly, only GCN[11] expansion was found in two
patients, indicating that they are homozygous carriers
(Fig. 2, right panel). Consistently, a manual control of the
FDSTools output clearly distinguished between the genuine
allele and stutters or PCR errors. Together, this procedure
suggests that heterozygosity of familial GCN[13–16]
expansion variants could be accurately determined by the
fast and simple DNA Bioanalyzer procedure. Identiﬁcation
of exact repeat lengths and shorter expansion variants
require MPS sequencing at sufﬁcient depth and
proper sequence analysis to discriminate short stutters from
the genuine alleles.
To assess the prevalence of stutters we focused on the
GCN[10] allele in all samples (controls and OPMD) and
found a common shorter trinucleotide stutter (−1) (Fig. 3a).
The (−1) stutter was found in all samples regardless
of genotype, DNA extraction procedure, or the source of
bioﬂuid (Fig. 3a). To assess reproducibility of the results, the
procedure was repeated twice. In the ﬁrst experiment the
ﬁrst target-speciﬁc PCR ampliﬁcation was carried out with
20 cycles, and in the second experiment with 40 cycles.
Overall, genotyping was consistent in both experiments.
However, a higher percentage of stutter was found in the
40-cycle PCR protocol (Fig. 3a). In addition, higher stutter
percentage was also found in samples with low reads,
Fig. 1 A ﬂowchart of the DNAseq procedure
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Fig. 2 Examples of bioanalyses and FDSTools sequence results in
OPMD and controls. Each row shows the result from a single subject.
The left panel shows DNA histograms, which were generated by the
DNA Bioanalyzer application. The right panel shows the graphical
output of FDStools sequence analysis for an anonymous control and
OPMD patients with ﬁve different GCN expansion lengths. The
genuine alleles are highlighted in bold. The wild-type allele is depicted
in black and the expanded allele in red. Non-genuine reads (PCR
stutters, PCR-generated point mutations and sequencing errors) are
shown in gray
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indicating that reliable genotyping requires deeper sequen-
cing output (between 5000 and 10,000 reads per sample).
However, a sequencing depth around 1000 reads per sample
was also found to be reliable. We found that the complexity
of stutters increased with the longer expansion variants
(Fig. 3b). In patients with the GCN[16], allele stutters were
more abundant compared with the shorter expansions. Most
often stutters were shorter (−1 to −3) (Fig. 3b). In only one
case, (GCN[15]) a+ 1 stutter was found (Fig. 3b), but that
+1 stutter could not be reproduced.
Stutters are common artefacts when amplifying repetitive
regions [9, 19]. Accurate diagnosis requires discrimination
of stutters from the genuine alleles, which is not possible
with traditional Sanger DNA sequencing [20]. Moreover,
Sanger sequencing does not accurately differentiate
between two alleles of different lengths, and thus it is not
suitable to determine heterozygosity. Overall, most diag-
nosis of trinucleotide expansion variants is carried out with
a Sanger sequencing [11, 21]. In contrast to Sanger
sequencing, MPS can generate sequencing reads of sufﬁ-
cient depth allowing overcoming sequencing errors. In
combination with FDSTools STR stutters can be identiﬁed,
and the genuine alleles can be discriminated from stutters.
Apart from discriminating genuine alleles from stutters we
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Fig. 3 Stutters in trinucleotide GCN expansion. a Analysis of the wild-
type allele (GCN[10]) in control and OPMD patients. The number of
reads (left panel) or the percentage of reads with respect to the highest
allele in the sample (right panel) are plotted against GCN length
results. In the control group, results are from one PCR experiment. In
the OPMD group, results are from two experiments: 20 ampliﬁcation
cycles (PCR1) or 40 ampliﬁcation cycles (PCR2). The stutter per-
centage was signiﬁcantly higher in the second experiment. Genuine
allele length is depicted in bold and stutter allele length is in plain text.
P-value was calculated by the Student’s T-test. b Analysis of
sequencing results in OPMD subjects from two experiments. Plots
show percentage of reads with respect to the highest allele in the
sample for subjects with the same genotype (heterozygous: GCN[12],
GCN[13], GCN[14], GCN[15], GCN[16], and homozygous GCN
[11]). In each plot, the left side shows the wild-type GCN[10] and
corresponding stutter GCN[9], the right side shows the expanded allele
and its corresponding stutters. Genuine GCN length is depicted in bold
and stutters are plain. Each dot represents an individual. Median is
marked with a black line
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show that optimization of the PCR protocol can sig-
niﬁcantly reduce stutter formation in PCR.
From the 50 OPMD subjects that were included in this
study, two subjects from OPMD families had muscle
weakness complaints but did not have a trinucleotide
expansion variant. From the 48 genetically conﬁrmed
OPMD subjects, a familial GCN expansion was found for
35 subjects (73%). The other 13 subjects were either non-
familial (sporadic), or unknown familial genetic background
(Table S1). The range of GCN expansions varied between
GCN[11] to GCN[16] (Table S1). Heterozygosity for GCN
[10]/GCN[16] was most abundant among the familial sub-
jects, but no speciﬁc preference of expansion variants was
found in the sporadic cases (Fig. 4). However, the small
number of subjects limits statistical tests.
In a previous study, we used Sanger sequencing for DNA
diagnosis [22]. Nine subjects were included in both studies,
and discrepancies between GCN expansion length were
found for only three patients. Two non-familial patients
were diagnosed as GCN[13] with Sanger sequencing, but
with MPS were found to have GCN[14]. One patient was
diagnosed with GCN[14] with Sanger sequencing, but GCN
[16] was found with the MPS. Four family members of this
patient also have GCN[16], which supports an accurate
diagnosis with MPS. The higher prevalence of GCN[16]
variant in this Dutch OPMD cohort is in contrast to other
national studies. Those studies showed that the GCN[13]
variant is the most abundant [23]. In a French OPMD
cohort, heterozygous GCN[13] was the most abundant,
whereas the GCN[16] variant was rare [14]. In Mexico, the
GCN[15] variant is the most abundant (65% (66 out of
102). Heterozygous compound variants were reported very
rarely [14, 24, 25]. As those were not conﬁrmed by other
procedures, it could be a mistake of the Sanger results.
Homozygous GCN[11] were found in both French and
Dutch studies. OPMD patients with the GCN[11] variant
are not common [23], but heterozygous GCN[11] was
reported in the general population, estimated as 0.05–2%
[17, 26]. As those studies were carried out with the Sanger
sequencing, this non-pathogenic polymorphism should be
conﬁrmed using MPS with FDSTools analysis. Moreover,
we found major differences in clinical severity between the
two GCN[11] homozygous subjects, albeit a close family
relationship and only one year difference in age. The
brother has swallowing dysfunction, severe ptosis for which
an unsuccessful surgery was tried, and severe leg
muscle weakness resulting in wheelchair dependence. In
contrast, his sister had minor swallowing dysfunction in
clinical testing without other signs of weakness. She
underwent an eyelid correction in the past. Together, it is
unclear why certain heterozygous GCN[11] cases
develop muscle weakness later in life [14 and this study],
but others have severe muscle weakness (this study).
This supports our hypothesis that secondary aging-
associated triggers are involved in symptom manifestation
in OPMD [27].
We then investigated a correlation between genetics and
clinical or demographic features (Table 1). No signiﬁcant
correlation was found between GCN expansion length and
clinical features in OPMD patients (Table 1). This obser-
vation is consistent with a study assessing a phenotype–
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Fig. 4 The frequency of GCN expansion length in the Dutch OPMD
patients. Bar chart shows the frequency of GCN expansion variants in
familial and sporadic OPMD. The GCN[16] expansion is enriched in
the Dutch familial OPMD. The GCN[15] expansion is found only in
sporadic OPMD, the GCN[11] expansion is only familial
Table 1 Pearson correlation in conﬁrmed expPABPN1 carriers between age, family, GCN length, and symptom severity
Pearson r
Age Gender GCN expansion length Symptom severity Diagnosis duration First feature
p-value Age 0.132 −0.237 0.471 0.231 −0.002
Gender 0.372 −0.021 0.032 0.039 0.184
GCN expansion length 0.105 0.886 0.080 −0.016 0.166
Symptom severity 0.001 0.827 0.589 0.052 0.482
Diagnosis duration 0.126 0.801 0.919 0.736 −0.126
First feature 0.992 0.236 0.289 0.001 0.440
Symptom severity: mild (one muscle is affected); severe (two or more muscles are affected). First features: clinical features: ptosis, dysphagia or
leg weakness. p-value was calculated by the Pearson test. Sinigicant correlations are in bold.
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genotype relation in a Spanish OPMD study [28], and with
our previous study in a smaller Dutch OPMD cohort [22].
However, two other studies suggested a weak correlation
between GCN expansion length and age of onset [14, 24].
In addition, in this study, we found a signiﬁcant correlation
between age and symptom severity (r= 0.471, p-value
0.001), which is consistent with our previous study [22]. In
addition, in this Dutch OPMD cohort we also found a sig-
niﬁcant correlation between the initial features (ptosis,
dysphagia, or leg weakness) and symptom severity (r=
0.482, p-value 0.001). Patients with initial leg weakness
symptoms were more severe. It is yet obscure whether in
OPMD, alanine expansion length affects muscle weakness
severity. Recent studies suggested that additional factors,
other than the known genotype, could modulate disease
severity [29]. Our previous studies suggested that aging
factors could affect symptom initiation [27]. In addition, the
correlation between initial clinical features and severity
suggests that muscle-speciﬁc factors could modulate
symptom severity.
Several studies suggested that OPMD is under-diagnosed
[6, 7], in part, because OPMD is aging associated [27], thus
it is likely that the patients with a late onset are mis-
diagnosed or not subjected to DNA diagnosis. In addition,
OPMD genetics is variable: most reported patients are
heterozygous dominant [14, 23, 30]. Homozygous domi-
nant patients are very rare [14, 15]. Few recessive OPMD
cases were also reported [31, 32]. The variability of
symptoms and progression in OPMD could also contribute
to misdiagnosis. We present a procedure for accurate gen-
otyping of trinucleotide expansion regions. Advances in
DNA sequencing reveal that missing alleles (deleted or
allelic dropouts) can lead to misdiagnosis [33]. With MPS
we still cannot recognize those cases and thus
cannot exclude the possibility that those cause OPMD.
Moreover, allelic dropouts were recently recognized in tri-
nucleotide expansion repeats using Pac-Bio sequencing
[20]. For accurate OPMD diagnosis and an assessment of
the spectrum of OPMD genetics, additional studies are
required.
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